Sylvester Comprehensive Cancer Center

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • AL3818-US-002 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:

    IRB: 20170218

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary

    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    AL3818-US-002: A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma

    Eligibility Criteria - NCT02584478 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170846 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:

    IRB: 20170846

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer

    Eligibility Criteria - NCT03367871 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190887 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Violeta Milic
    RCphone 305-243-5181

    IRB: 20190887

    SDG: Gynecologic Cancer
    Disease Site(s):

    Lung,Ovary

    Sponsor: MER

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

    Eligibility Criteria - NCT03319628 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200931 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Violeta Milic
    RCphone 305-243-5181

    IRB: 20200931

    SDG: Gynecologic Cancer
    Disease Site(s):

    Corpus Uteri

    Sponsor: GOG Foundation

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial Cancer

    Eligibility Criteria - NCT04393285 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211145 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20211145

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Ovary

    Sponsor: Seagen Inc

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

    Eligibility Criteria - NCT04665921 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple

    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB

    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200854 - Penedo Frank

  • Investigator:
    Frank Penedo
    RCname Email

    Coordinator:

    IRB: 20200854

    SDG: Population Sciences
    Disease Site(s):

    Ovary

    Sponsor: NCI

    Enrolling Sites:

    Gables
    Kendall
    Sylvester

    Title:

    Living Well: A Web-Based Program to Improve Quality of Life in Rural and Urban Ovarian Cancer Survivors

    Eligibility Criteria - NCT04533763 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    SDG: Colorectal Cancer
    Disease Site(s):

    Multiple

    Sponsor: TSB

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • 20150600 - Schlumbrecht Matthew

  • Investigator:
    Matthew Schlumbrecht
    RCname Email

    Coordinator:

    IRB: 20150600

    SDG: Gynecologic Cancer
    Disease Site(s):

    Ovary

    Sponsor: NCI

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    Use of CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

    Eligibility Criteria - NCT00539162 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201370 - Sinno Abdulrahman

  • Investigator:
    Abdulrahman Sinno
    RCname Email

    Coordinator:

    IRB: 20201370

    SDG: Gynecologic Cancer
    Disease Site(s):

    Ovary

    Sponsor: M.D. ANDERSON

    Enrolling Sites:

    Sylvester

    Title:

    2020-0165: Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE)

    Eligibility Criteria - NCT04575935 *This information has been extracted from " www.clinicaltrials.gov"

  • SPN-00714 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190673

    SDG: Other
    Disease Site(s):

    Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"